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Interleukin-22 Promotes Wound Repair in Diabetes
by Improving Keratinocyte Pro-Healing Functions
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Giovanna Zambruno4, Andrea Cavani1 and Francesca Cianfarani4
Impaired re-epithelialization, imbalanced expression of cytokines and growth factors, and vascular disease
contribute to healing impairment in diabetes. IL-22, a pro-inﬂammatory cytokine mediating a cross-talk between
immune system and epithelial cells, has been shown to have a role in repair processes. In this study we aimed to
investigate IL-22 regenerative potential in the poor healing context of diabetic wounds. By using streptozotocin-
induced diabetic mice, we demonstrated that IL-22 wound treatment signiﬁcantly accelerated the healing
process, by promoting re-epithelialization, granulation tissue formation, and vascularization. Improved
re-epithelialization was associated with increased keratinocyte proliferation and signal transducer and
activator of transcription 3 (STAT3) activation. We showed that endogenous IL-22 content was reduced at both
mRNA and protein level during the inﬂammatory phase of diabetic wounds, with fewer IL-22-positive
cells inﬁltrating the granulation tissue. We demonstrated that IL-22 treatment promoted proliferation and
injury repair of hyperglycemic keratinocytes and induced activation of STAT3 and extracellular signal–regulated
kinase transduction pathways in keratinocytes grown in hyperglycemic condition or isolated from
diabetic patients. Finally, we demonstrated that IL-22 treatment was able to inhibit diabetic keratinocyte
differentiation while promoting vascular endothelial growth factor release. Our data indicate a pro-healing
role of IL-22 in diabetic wounds, suggesting a therapeutic potential for this cytokine in diabetic ulcer
management.
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INTRODUCTION
Chronic diabetic ulcers fail to proceed through biological
events characterizing acute repair. Re-epithelialization, new
vessel formation, growth factor production, and immune
responses are among those functions altered in diabetic ulcers
(Loots et al., 1998; Werner and Grose, 2003; Pukstad et al.,
2010).
IL-22 is a cytokine involved in host defense at epithelial
surfaces and in modulation of tissue responses during
inﬂammatory conditions, including psoriasis and rheumatoid
arthritis (Ikeuchi et al., 2005; Zheng, 2007; Wolk et al., 2009).
IL-22 is produced by different cell types of innate and
adaptive immunity (Trifari et al., 2009; Witte et al., 2010), but
the expression of IL-22 receptor complex, IL-22R1/IL-10R2, is
mainly conﬁned to epithelial cells of the skin, pancreas,
intestine, liver, and lung (Wolk et al., 2004). Binding of IL-22
to its receptor activates the signal transducer and activator of
transcription (STAT) pathway, in particular STAT3, and the
mitogen-activating peptide kinase pathway (Lejeune et al.,
2002).
An important role of IL-22 in repair processes has been
emerging in the last decade. IL-22 has been described as
involved in liver, colon, thymus, and airway epithelial
regeneration (Pickert et al., 2009; Ren et al., 2010; Pociask
et al., 2013). In the epidermis, IL-22 induces hyperplasia,
inhibiting keratinocyte differentiation, while promoting migra-
tion and pro-inﬂammatory gene expression (Boniface et al.,
2005). IL-22− /− mice display delayed cutaneous wound
healing (McGee et al., 2013). A beneﬁcial effect of IL-22
has been described in metabolic disorders of diabetic mice,
where IL-22 improves insulin sensitivity, preserves gut
mucosal barrier, and decreases chronic inﬂammation (Wang
et al., 2014). On the basis of this evidence, we evaluated the
effects of IL-22 administration to diabetic wounds and
speciﬁcally investigated the response of diabetic keratinocytes
to IL-22 treatment.
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RESULTS
IL-22 topical treatment accelerates diabetic wound closure by
improving re-epithelialization
To evaluate the effect of IL-22 in diabetic wound healing,
wounds of diabetic and nondiabetic mice were treated with
recombinant mouse IL-22 or with saline control solution.
Wound area analysis indicated a signiﬁcant reduction in IL-22-
treated diabetic wounds when compared with saline-treated
diabetic controls, starting from day 4 and until day 13 after
induction (Figures 1a and b) (Po0.05). No signiﬁcant
difference was observed at any time point between nondiabetic
and IL-22-treated diabetic mice. All IL-22-treated diabetic
wounds healed by day 19 as nondiabetic controls. In contrast,
60% of saline-treated diabetic wounds were not jet healed at
that time point (Figure 1b). Cytokine treatment in nondiabetic
wounds revealed no signiﬁcant healing improvement with
respect to nondiabetic saline-treated controls (not shown).
To further analyze the effects of IL-22 in diabetic
wound healing, histological, and immunohistochemical ana-
lyses were performed on 7-day wound biopsies. Re-epithe-
lialization, measured as the percentage of distance covered
by the epidermis between the wound edges (Semenova et al.,
2008), was signiﬁcantly increased in IL-22-treated diabetic
wounds as compared with diabetic controls (57.7± 4.3%
in diabetic+IL-22 versus 45.5±3.1% in diabetic+saline,
Po0.05) (Figures 1c and e). Wound contraction, measured
as the distance between wound edges, revealed a slight
(not signiﬁcant) increase in IL-22-treated diabetic wounds
(Figure 1f). Moreover, immunohistochemistry for the proli-
feration marker Ki67 revealed a signiﬁcantly higher percen-
tage of proliferating keratinocytes in the epidermis of
IL-22-treated diabetic wounds (54.46± 3.04% in diabetic
+IL-22 versus 41.7± 2.2% in diabetic+saline, Po0.05)
(Figures 1d and g).
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Figure 1. Wound-healing analysis in IL-22-treated diabetic wounds. (a) Representative pictures of IL-22- or saline-treated diabetic and nondiabetic wounds at
days 0, 7, and 13 after injury. (b) Wound-closure analysis of IL-22-treated diabetic (triangles), saline-treated diabetic (circles), and untreated nondiabetic wound
areas (squares), (n=12 per group). *Po0.05. (c) Composite pictures of 7-day hematoxilyn and eosin-stained central wound sections of nondiabetic, saline-, and
IL-22-treated diabetic wounds. Epithelial tongues (dashed lines) and wound edges (arrows), identiﬁed by the most proximal hair follicle, are highlighted. Vertical
lines indicate picture arrangement. Bars=400 μm. (d) Ki-67 immunostaining showing proliferating keratinocytes (arrows) in the epidermis (e). Bars= 200 μm.
(e–g) Quantitative analysis of re-epithelialization (percentage of distance covered by epidermis) (e), contraction (distance between wound margins) (f),
proliferation (percentage of Ki67-positive keratinocytes) (g). (n= 8–11 per group), *Po0.05.
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IL-22 administration to diabetic wounds associates with
improved granulation tissue formation, maturation, and
vascularization
Granulation tissue formation was analyzed by staining central
wound sections with Masson’s trichrome. Results showed that
the granulation tissue area was signiﬁcantly larger in IL-22-
treated wounds compared with saline-treated controls (1.17±
0.22mm2 versus 0.55± 0.08mm2, Po0.05) (Figures 2a and
c). Moreover, IL-22-treated diabetic wounds also manifested
a more mature granulation tissue, largely ﬁlled with collagen
(green staining) and invading cells, with respect to saline-
treated diabetic specimens, almost exclusively ﬁlled with
ﬁbrin (red staining) and poorly cellularized. Immunohisto-
chemical analysis with an anti-PECAM/CD31 (platelet
endothelial cell adhesion molecule-1) antibody revealed
signiﬁcantly increased vascular density in IL-22-treated
diabetic wounds (38.5± 2.1 vessels per mm2 in diabetic
+IL-22 versus 27.2± 3.02 in diabetic controls, Po0.05)
(Figures 2b and d). All parameters analyzed were similar in
IL-22-treated diabetic wounds and nondiabetic untreated
controls.
IL-22 expression is reduced in diabetic wounds
To evaluate whether the perturbed diabetic wound-healing
process could correlate with altered IL-22 production, IL-22
was analyzed by real-time reverse transcriptase–PCR in RNA
extracted by wound biopsies collected at different time points
after injury (Figure 3a). In both diabetic and nondiabetic
wounds, IL-22 mRNA, undetectable in unwounded skin, was
upregulated at day 1 after injury, reaching highest levels
at day 3 and then decreasing until day 13. However, in
diabetic mice, IL-22 mRNA levels were signiﬁcantly lower
compared with nondiabetic controls at 1, 3, and 7 days (day
1: 1 in diabetic mice, reference value, versus 6.82±2.55 in
controls; day 3: 5.27±0.79 versus 13.53± 1.2; day 7:
2.01± 1.41 versus 5.8± 2.01, Po0.05). At day 13, IL-22
mRNA levels were similar in both conditions (Figure 3a).
ELISA analysis conﬁrmed that IL-22 was undetectable in
nondiabetic and diabetic unwounded skin, and that IL-22
induction reached the maximal level at day 3 after injury, when
cytokine content was signiﬁcantly lower in diabetic wounds
(40.92±8.52 versus 67.63±9.6 pgml−1, Po0.05) (Figure 3b).
Immunohistochemistry with an anti-IL-22 antibody showed
that the IL-22-positive cell number was reduced in day-3 dia-
betic wounds with respect to nondiabetic controls (307.63±
64.11 versus 483.79± 37.00 cells per mm2, Po0.05)
(Figures 3c and d).
IL-22 accelerates in-vitro wound healing of hyperglycemic
keratinocytes
To speciﬁcally investigate IL-22 activity on diabetic keratino-
cytes, we performed an in vitro injury assay on monolayers of
normal human keratinocytes grown in normoglycemic
(Norm), hyperglycemic (D-glu), or osmolarity control (L-glu)
culture conditions, treated or not with IL-22 (Figure 4a). The
absence of toxic effects on cell viability was veriﬁed with the
LDH (lactate dehydrogenase activity) assay on keratinocytes
treated with 50mM of D- and L-glucose (data not shown). As
expected, 16 hours after injury, D-glu-treated keratinocytes
displayed signiﬁcantly delayed closure with respect to Norm
or L-glu-treated cells (87.2%± 0.2 of initial wounded area in
D-glu, 52.2%± 1.8 in Norm and 55.3± 1.3 in L-glu). IL-22
treatment promoted repair in all culture conditions (3.5%±
0.4 of initial wounded area in Norm, 2.4%± 0.7 in L-glu and
9.2%±0.9 in D-glu, Po0.05) (Figure 4b).
Keratinocyte proliferation was analyzed by BrdU incor-
poration analysis. Reduced basal proliferation of D-glu-treated
keratinocytes was observed (0.6± 0.19 in D-glu versus
1± 0.11 in Norm, reference value). After 24 hours of
stimulation, IL-22 signiﬁcantly induced proliferation in all
culture conditions, recovering the proliferative defect of
D-glu-treated cells with respect to controls (1.3± 0.02 in
Norm, 1.18±0.07 in L-glu and 1.14± 0.2 in D-glu, Po0.05).
These data indicate that IL-22 efﬁciently induced migration
and proliferation in both normoglycemic and hyperglycemic
conditions, recovering the defective behavior of diabetic
keratinocytes.
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Figure 2. IL-22 effects in diabetic wounds. (a and b) Seven-day central
sections from nondiabetic, saline-treated, and IL-22-treated diabetic wounds.
(a) Masson’s trichrome staining for evaluation granulation tissue (gt) extension
and composition. Dashed lines mark the lower boundary between granulation
tissue and subcutaneous panniculum carnosum. Bars=400 μm. (b) Anti-
platelet endothelial cell adhesion molecule-1 (PECAM/CD31) immunostaining
showing blood vessel distribution into granulation tissue. Bars= 100 μm.
(c and d) Quantitative analysis of granulation tissue area (c), vessel density
(d), n= 8–11 per group. *Po0.05; **Po0.01.
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IL-22 induces STAT3 and ERK1/2 phosphorylation in diabetic
keratinocytes
To verify whether IL-22 treatment was able to activate the
canonical STAT3 and extracellular signal–regulated kinase
(ERK) intracellular signaling in diabetic keratinocytes, western
blot analysis was performed in IL-22-treated normoglycemic
and hyperglycemic keratinocytes. IL-22 induced STAT3
phosphorylation in all culture conditions analyzed with a
similar fold induction (2.8± 0.2 for Norm; 3.0± 0.3 for L-glu;
3.6±0.1 for D-glu, Po0.05) (Figure 5a). Immunohistochemistry
with an anti-phospho STAT3 antibody on murine diabetic
wounds revealed that IL-22 was able to activate STAT3 in a
signiﬁcantly higher percentage of proliferating keratinocytes
compared with saline-treated controls (48.59%±8.3 versus
27.01%±2.6, Po0.01) (Figure 5e). IL-22 also induced ERK1/2
phosphorylation in hyperglycemic cultured keratinocytes, with
a fold increase similar to those exhibited by normoglycemic
and L-glucose-treated cells (2.5±0.7, 2.4±0.1, and 2.3±0.2,
respectively, Po0.05) (Figure 5b).
In parallel, signaling activation was analyzed on primary
keratinocytes from diabetic and nondiabetic individuals.
STAT3 phosphorylation was signiﬁcantly induced by IL-22
in both specimens, but induction observed in diabetic
cells was signiﬁcantly higher as compared with nondiabetic
ones (3.6± 0.3 versus 1.9± 0.1, Po0.05) (Figure 5c). IL-22
triggered ERK1/2 phosphorylation to a similar extent in
diabetic and nondiabetic keratinocytes (2.4±0.1 versus
2.5± 0.1, Po0.05) (Figure 5d). These results demonstrated
that IL-22 is able to drive STAT3 and ERK activation in
diabetic keratinocytes.
IL-22 modulates Keratin 1 and Involucrin expression and VEGF
secretion in diabetic keratinocytes
IL-22 has an anti-differentiating role in keratinocytes also by
inhibiting the expression of the differentiation marker keratin-
1 (KRT1), in a STAT3-dependent manner (Sestito et al., 2011).
To analyze whether IL-22 was able to counteract excessive
differentiation that afﬂicts diabetic keratinocytes (Sprachikov
et al., 2001), we evaluated the expression of the differen-
tiation markers KRT1 and involucrin (INV). IL-22 was added
in the culture medium of keratinocytes of diabetic and
nondiabetic individuals induced to differentiate by 4 days
over conﬂuence growing.
In sub-conﬂuent cells (days 0), KRT1 and INV expression
levels were signiﬁcantly higher in diabetic keratinocytes (fold
increase: 1.9± 0.1 for KRT1 and 1.3± 0.05 for INV in diabetic
versus nondiabetic). After differentiation induction, KRT1 and
INV were signiﬁcantly induced in both cell types, in basal
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Figure 3. IL-22 expression in diabetic and nondiabetic wounds. (a) Real-time PCR analysis of mouse IL-22 mRNA at different time points after wound induction
in diabetic and nondiabetic mice. Results are expressed as relative fold induction versus IL-22 expression at day 1 in diabetic mice (n=3; *Po0.05; **Po0.01).
(b) ELISA analysis for IL-22 contentin protein extracts from nondiabetic and diabetic wounds at different time points (n=3; *Po0.05). (c) Immunohistochemistry
with anti-mouse IL-22 antibody on day-3 sections of nondiabetic and diabetic wounds showing IL-22-positive cells inﬁltrating granulation tissue. Bars=100 μm.
(d) Quantiﬁcation of IL-22-positive cell density on wound tissue sections taken at different time points after injury in nondiabetic and diabetic mice (n=4;
*Po0.05).
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condition (3.0± 0.2 in nondiabetic, 9.0±0.3 in diabetic, for
KRT1; 1.7± 0.1 in nondiabetic, 2.3± 0.03 in diabetic, for
INV, fold increase versus nondiabetic basal level, Po0.05).
IL-22 treatment was able to exert its anti-differentiating role by
restoring KRT1 and INV levels in both nondiabetic and
diabetic keratinocytes (fold increase: 0.83± 0.2 and
1.83± 0.2, respectively, for KRT1; 1.2± 0.08 and 1.29± 0.1
for INV, Po0.05) (Figures 6a and b).
Having found increased vessel density in IL-22-treated
diabetic wounds, we investigated whether IL-22 could
promote pro-angiogenic factor vascular endothelial growth
factor (VEGF) secretion in keratinocytes. VEGF release was
analyzed by ELISA assay in supernatants of keratinocytes from
diabetic patients and nondiabetic controls, treated or not with
IL-22. VEGF secretion was reduced in diabetic keratinocytes
compared with controls, in basal condition (0.5± 0.09 fold
changes). IL-22 treatment signiﬁcantly stimulated VEGF
production in both diabetic and nondiabetic cells
(1.15± 0.28 in diabetic; 2.3± 0.05 in nondiabetic, over
untreated nondiabetic, Po0.05) (Figure 6c).
DISCUSSION
During cutaneous wound healing, early inﬂammatory
responses occur, thus preventing infections and enhancing
repair via the release of cytokine signaling between immune
and other skin cell populations. Growing evidences point to
IL-22 as a cytokine involved in repair events. IL-22 pro-
healing functions were described in studies on keratinocytes
(Boniface et al., 2005; Eyerich et al., 2009) and on different
models of epithelial regeneration (Pickert et al., 2009; Ren
et al., 2010; Dudakov et al., 2012; Pociask et al., 2013);
however, a description of the biological effects induced by
IL-22 in cutaneous wound healing is still lacking. In this study,
we asked whether IL-22 could contribute to restore wound-
healing processes altered in diabetic skin. We used
streptozotocin-induced type I diabetic mice, manifesting
wound-healing impairment, and used to test molecules with
therapeutic potential for diabetic wounds (Graiani et al.,
2004; Fadini et al., 2010; Lim et al., 2015). We found that
IL-22 treatment signiﬁcantly accelerated diabetic wound
closure, improving it to the levels of nondiabetic wounds. In
particular, IL-22 promoted diabetic wound re-epithelializa-
tion, also by increasing the number of proliferating keratino-
cytes in the epithelial tongue of diabetic lesions. In-vitro
analysis revealed that IL-22 is able to directly stimulate
migration and proliferation in hyperglycemic keratinocytes.
Improved re-epithelialization might also be due to inhibition
of terminal keratinocyte differentiation, as this was shown to
be the mechanistic basis of the observed IL-22-induced
epidermal hyperplasia in a model of reconstituted human
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epidermis (Boniface et al., 2005). Keratinocyte differentiation
and their consequent capacity to proliferate are reﬂected by
keratin expression pattern. In particular, KRT1 is associated
with differentiating cells of suprabasal epidermal layers
(Koster, Roop, 2007) and excessive differentiation is a
typical feature of diabetic keratinocytes (Sprachikov et al.,
2001). IL-22 was previously shown to downregulate KRT1
expression via STAT3 activation (Sestito et al., 2011). In line
with these observations, we found that KRT1 expression is
higher in diabetic keratinocytes than in nondiabetic control
cells, and that IL-22 treatment sensibly reduces KRT1 levels
also in the more differentiated diabetic keratinocytes.
Analogous results were obtained analyzing IL-22 effects on
INV expression.
Conﬁrming previous reports about a central role for STAT3
as the mechanistic basis for skin remodeling and keratinocyte
migration (Sano et al., 1999; Kira et al., 2002), we show that
IL-22 signiﬁcantly induces STAT3 phosphorylation both
in vitro in hyperglycemic and diabetic patients keratinocytes
and in vivo in keratinocytes of diabetic murine wounds
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Figure 5. Signal transducer and activator of transcription 3 (STAT3) and extracellular signal–regulated kinase (ERK) signaling analysis in IL-22-treated diabetic
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Composite images (c and d) are related to different parts of the same gel. (e) P-STAT3 immunostaining on 7-day nondiabetic and diabetic mouse wounds treated
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treated with IL-22. Besides STAT3, IL-22 also induces the
activation of the keratinocyte pro-proliferative and pro-
survival ERK1/2 pathway (Pastore et al., 2005; Zhang et al
2012), in both hyperglycemic and diabetic patient
keratinocytes.
IL-22-treated diabetic wounds also exhibited granulation
tissue formation to a level comparable to normal wounds. In
the skin, only keratinocytes and, to a minor extent, dermal
ﬁbroblasts express IL-10R/IL-22R, thus being IL-22 targets
(Wolk et al., 2009). Thus, the improvement of granulation
tissue extension in diabetic wounds treated with IL-22 could
be attributed to a direct action on dermal ﬁbroblasts, with a
consequent stimulation of extracellular matrix protein deposi-
tion. In parallel, we can also hypothesize an indirect
stimulation of ﬁbroblasts by growth factors released by
IL-22-activated keratinocytes.
Importantly, we found that IL-22 administration also
associated with increased vascular density in diabetic
wounds, where vessel density reached values similar to those
of nondiabetic controls. This effect is highly relevant for the
rescue of diabetic wound repair impairment, as vascular
complications are regarded as the leading cause of defective
healing in diabetes. VEGF expression is reduced in diabetic
ulcers (Frank et al., 1995) and VEGF treatment accelerates
diabetic healing by promoting angiogenesis (Romano Di
Peppe, Mangoni, 2002; Galiano et al., 2004). The observed
angiogenic effect cannot be directly induced by administered
IL-22, as endothelial cells lack IL-22 receptor (Wolk et al.,
2009). During wound healing, actively proliferating keratino-
cytes are an important source of VEGF that stimulates
proliferation and tropism of endothelial cells into the
granulation tissue (Brown et al., 1992). We found that IL-22
promotes VEGF secretion in diabetic keratinocytes. Moreover,
STAT3 is a transcription activator for VEGF, whose expression
is silenced following STAT3 targeting (Xu et al., 2005).
Therefore, STAT3 activation mediated by IL-22 may modulate
VEGF secretion in both nondiabetic and diabetic keratino-
cytes, thus indirectly supporting the increased blood vessel
density observed in IL-22-treated wounds. The effects of IL-22
in the diabetic wound might be of high clinical relevance, as
we observed signiﬁcantly reduced cytokine levels at early
time points, reﬂected by the decreased number of IL-22-
positive cells at the wound site. Efﬁcient immune responses
are essential for tissue repair outcome (Schaffer, Barbul,
1998). CD4+ T lymphocyte–impaired recruitment, functional
reduction, and lower cytokine secretion capacity have been
described in human chronic lesions (Loots et al., 1998;
Toulon et al., 2009). We showed how IL-22 expression was
undetectable in both normal and diabetic unwounded skin.
After wound induction, we observed a time-regulated
increase in IL-22, signiﬁcantly reduced in diabetic condition.
Proliferation of resident skin γ/δT cells, among major IL-22
producers, is compromised in diabetic mice (Taylor et al.,
2010). However, increased IL-22 circulating levels were
described in type II diabetic patients (Guo et al., 2014; Zhao
et al., 2014). We can then hypothesize that reduced IL-22
content in diabetic wounds could be determined by a local
impaired activation of these cell populations, in addition to
altered recruitment of circulating immune cells producing
IL-22 into the diabetic wound tissue, a microenvironment not
obviously mirroring the systemic situation. Further investiga-
tions will be necessary to characterize the immunological
proﬁle of these IL-22-positive cells.
In conclusion, our results indicate an innovative role for
IL-22 in diabetic wound repair, exerted not only by improving
re-epithelialization, granulation tissue deposition, and vascu-
larization but also by modulating keratinocyte differentiation
and VEGF production. Globally, our data suggest IL-22 as a
potential tool for therapeutic treatment of diabetic wounds.
MATERIALS AND METHODS
Diabetic mice and wound-closure analysis
Animal experiments were approved by the Istituto Dermopatico
dell'Immacolata, IDI-IRCCS Animal Care and Use Committee. Six-
week-old Balb/c male mice (Harlan Laboratories, San Pietro al
Natisone, Italy) were rendered diabetic by a single intraperitoneal
injection of streptozotocin (180mg kg− 1) (Sigma-Aldrich, St. Louis,
MO). After 1 week, blood glucose levels were measured and mice
with glycemia ranging between 285mg dl− 1 (minimum level) and
590mg dl− 1 (maximum level) were used 3 weeks later for wound
experiments (average glycemic levels: 476mg dl−1). During experi-
mental procedures, diabetic mice were weekly weighted and
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Figure 6. Keratin 1 (KRT1) and involucrin (INV) expression and vascular
endothelial growth factor (VEGF) production in IL-22-treated diabetic
keratinocytes. (a) Western blot analysis and relative densitometric
quantiﬁcation of KRT1 (a) and INV (b) levels on protein lysates from diabetic
and nondiabetic keratinocyte strains treated or not (Unt) with 50 ngml−1 of
IL-22 for 48 hours. Analysis was performed on keratinocytes before and after
terminal differentiation achieved by growing cells for 4 days after conﬂuence
in the presence or absence of IL-22 (n=3; *Po0.05; **Po0.01). Western
blotting composite images are related to different parts of a same gel. (c) ELISA
assay measuring VEGF content in supernatants of human diabetic and
nondiabetic keratinocytes cultured for 24 hours in the presence or the absence
of IL-22 (n=3; *Po0.05).
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monitored for polyuria, polyphagia, polydipsia, and glycemia. Mice
manifesting a body weight loss above 20% or a poor motility were
excluded. Changes in body weight of the selected diabetic animals
were as follows: (average values ± s.d.): 20.62 g± 1.48 (before
treatment); 18.985 g±1.27 (1 week after streptozotocin);
18.385 g±1.14 (end of the experiment). A 6-mm-diameter
full-thickness excisional wound was performed on the dorsum
of diabetic and nondiabetic mice. At days 1 and 4 after injury,
1 μg of mouse recombinant IL-22 (R&D Systems, Abingdon,
UK) or analogous volume of saline control solution was
injected below the crust. Wound margin was traced on a
transparency ﬁlm at days 0, 1, and every third day thereafter
until closure. Wound areas were measured by a computer-
assisted image analyzer (KS300; Zeiss, Jena, Germany) and
the healing rate expressed as the percentage of initial area.
Histological and immunohistochemical analysis
Diabetic mice treated with IL-22 or saline and nondiabetic controls
were killed 7 days after wounding and wound biopsies excised,
paraformaldehyde ﬁxed, and parafﬁn embedded. Four-micrometer-
thick central wound sections were processed (Failla et al., 2000).
Ematoxilin/eosin and Masson’s trichrome staining (DakoCytomation,
Milan, Italy) were performed to analyze re-epithelialization and
granulation tissue formation, respectively. Antibodies used were as
follows: anti-PECAM/CD31 (M 20; Santa Cruz Biotechnology, Santa
Cruz, CA), anti Ki67 (Novocastra-Leica Microsystems, Milan, Italy),
anti-IL-22 (Novus Biologicals, Cambridge, UK) and anti P-STAT3
(Cell Signaling, Danvers, MA). Negative controls were obtained by
omitting primary antibody. Samples were quantiﬁed by computer-
assisted image analyzer (Zeiss). Analyses were performed by two
blinded operators on six to eight noncontiguous, randomly selected
ﬁelds/sample.
Real-time reverse transcriptase–PCR
Total RNA was extracted from wound biopsies and converted into
cDNA as described (Cianfarani et al. 2006). Real-time reverse
transcriptase–PCR was performed with SYBR Green PCR Master
Mix (Applied Biosystem, Foster City, CA) using the following
primers: IL-22 forward 5′-TCCGAGGAGTCAGTGCTAAA-3′, reverse
5′-AGAACGTCTTCCAGGGTGAA-3; glyceraldehyde-3-phosphate
dehydrogenase forward 5′-GTATGACTCCACTCACGGCAAA-3′,
reverse 5′-TTC-CCATTCTCGGCCTTG-3′. PCR products were measured
by the ABI PRISM 5700 detection system (Perkin-Elmer, Norwalk, CT)
and normalized to glyceraldehyde-3-phosphate dehydrogenase ampli-
ﬁcation. Quantiﬁcation was performed by the comparative CT method
(Pfafﬂ, 2001). All determinations were performed in triplicate.
Keratinocyte cultures
Primary cultures of human keratinocytes (Madonna et al., 2008) were
obtained from skin biopsies of three type II diabetic patients and three
healthy volunteers enrolled in the study after written informed patients
consent. The study was performed according to the Declaration of
Helsinki Principles with regard to scientiﬁc use and approved by the
ethical committee of Istituo Dermopatico dell'Immacolata, IDI-IRCCS.
Keratinocytes were grown in a serum-free keratinocyte growth
medium (KGM; Clonetics, Walkersville, MD), until 40–60% con-
ﬂuence. For conditions, 50 mM of D-glu and L-glu (Sigma Aldrich)
were added as hyperglycemic and osmolarity control condition,
respectively. All stimulations with recombinant human IL-22 (R&D
Systems) were performed in KBM.
Scratch and BrdU incorporation assays
Normo and hyperglycemic keratinocytes were grown to conﬂuence
on type IV collagen (20 μg ml−1) and then scratched with a P-200
pipette tip. Cultures were incubated with respective media contain-
ing or not human recombinant IL-22. The cell-free area was
measured with a computer-assisted image analysis system (Zeiss)
and expressed as the percentage of initial wounded area.
Normo and hyperglycemic keratinocytes were plated in 96-well
plates (2× 104 cells per well) and stimulated or not with human
recombinant IL-22 for 24 hours. BrdU was added 16 hours before the
end of the incubation time and its incorporation analyzed by using
the BrdU cell proliferation kit (Roche Applied Sciences, Mannheim,
Germany).
Western blot analysis
Cells were lysed in RIPA buffer containing protease and phosphatase
inhibitors (Roche). Proteins were resolved on a 10% SDS–PAGE,
transferred to polyvinylidene diﬂuoride ﬁlters, and probed with
primary antibodies. Filters were developed using the ECL-plus
detection system (Amersham Biosciences, Buckinghamshire, UK) or
the SuperSignal West Femto kit (Pierce, Rockford, IL) and probed
with phospho-YSTAT3 (Tyr 705) (Cell Signaling), STAT3, P-ERK1/2,
ERK1/2, β-actin (Santa Cruz Biotechnology), KRT1, and INV,
(Covance, Emeryville, CA). Immunoblots were quantiﬁed by imaging
densitometer (GS-670; Bio-Rad, Hercules, CA).
ELISA assay
Protein extracts from wound biopsies and cultured human keratino-
cytes were obtained as described (Odorisio et al., 2002). IL-22 and
VEGF were, respectively, quantiﬁed in wound extracts and kerati-
nocyte supernatants by using IL-22 murine Quantikine and VEGF
Quantikine Elisa Kits (R&D Systems).
Statistical analysis
Statistical signiﬁcance was determined using Student’s t-test. Values
were expressed as mean± s.d. P-values o0.05 were considered
statistically signiﬁcant.
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